

Mycology II

Candidiasis

Cryptococcosis






Aspergillosis

Mucormycosis

***Pneumocystis jirovecii* pneumonia**

7. 10. 2025

2. LF UK



Opportunistic fungal infections

Fungal infections affecting humans with **specific risk factors**

Cellular immune response impairment

Impairment of cutaneous or mucosal barrier

- Endogenous
- Exogenous

Never happen without risk factors in the host

Fungal infections – immune response

Major surgery, burn wounds,
major skin and soft tissue
wounds, ATB


Intravenous catheters

Diabetes mellitus: decreased
functions (chemotaxis,
phagocytosis, killing) of diabetic
polymorphonuclear cells and
diabetic monocytes/macrophages
compared to cells of controls

Glucocorticoids

Immunosuppressants
administered after bone
marrow and solid organ
transplantation or autoimmune
diseases

AIDS



Candidiasis

Mostly **endogenous** fungal infection except HAI (C. auris, other)

Superficial infections - Th 17 lymphocytes

Visible mucosal/cutaneous lesions

- Mucosal candidiasis – thrush, vaginal candidiasis
- Mucocutaneous candidiasis – rare innate immune deficiencies (STAT3 HIES, STAT1-C)
- Oesophagitis


Invasive infections – myeloid phagocytes

RF

- Major GIT surgery
- Intravascular catheters (parenteral nutrition)
- Neutropenia/cellular immune deficiency
- Broad spectrum antibiotics
- Premature newborns

- Bloodstream infections - candidaemia
- Organ candidiasis with/without candidaemia
- Disseminated candidiasis
- Candida UTI

Candidiasis – pathogenesis



Candidiasis – causative agents

Candida albicans, *Candida glabrata*, *Candida tropicalis*, *Candida parapsilosis* and *Candida krusei*

Candida – virulence factors

- Morphotype change (yeast – pseudohyphae – hyphae)
- Adherence and invasion of *Candida* spp. in endothelial and epithelial cells
- Biofilm formation

Candida – immune recognition and response

PRRs – myeloid phagocytes

TLR

The C-type lectin receptor (CLR) family of receptors – cascade activation – interleukin synthesis – Th1 and Th17 immune response

T-independent response

Neutrophils - oxidative + non-oxidative killing

Invasive candidiasis – clinical manifestation

Mild symptoms to severe sepsis, organ-specific (neutropenic)

Invasive candidiasis should be suspected in patients with known risk factors who have an unexplained fever that is unresponsive to antibacterial treatment

Invasive candidiasis – diagnostic options

- Microscopy, culture, antifungal susceptibility testing – blood, tissue
- Beta-D-glucan detection (serum)
- Mannan/antimannan detection (serum)
- PCR (panfungal – tissue, targeted)

Invasive candidiasis – treatment

1st line echinocandins

Targeted/step-down fluconazole/other azoles if susceptible
Amphotericin B (UTI, neonates, salvage)

Candida – antifungal resistance

- Echinocandins – FKS1/FKS2 mutations
- Azoles - ERG11 mutations
- Amphotericin B – *C. auris*

Cryptococcus neoformans

Infection source – contaminated soil, dust (bird droppings), **inhalation**

Risk factors

- Cellular immunodeficiency (macrophage – CD4+T-cell cooperation)

Pathogenicity factors

- Polysaccharide capsule
- Melanin
- Body temperature 37 °C survival and growth

Pathogenesis - after inhalation blastoconidia are engulfed by alveolar macrophages, but they survive, **dissemination in macrophages via blood and lymph, predilected localization: CNS**

Clinical manifestation: meningoencephalitis, disseminated disease in most cases, subacute/chronic course

Treatment amphotericin B + 5-FC, high-dose fluconazole, long-term

Aspergillosis

Source: environment - soil, pot flowers, food, household (conidia, inhalation)

Risk factors

- Neutropenia (neutrophils able to destruct conidia)
- T lymphocytes/macrophage impairment (leading to restricted ability to destruct hyphae)
- ICU treatment, mechanical ventilation, lung tissue destruction (viruses – influenza, SARS-CoV2)
- Chronic pulmonary disease

Causative agents: ***A. fumigatus***, *A. niger*, *A. flavus*, *A. terreus*

Pathogenicity factors

- Adherence – fibronectin, laminin (conidia)
- Gliotoxin (inhibits macrophage activity and T- cell proliferation)
- Enzymes - catalase, phospholipase, elastase, proteases

Aspergillosis – clinical forms

depends on host's condition

- **Allergic bronchopulmonary aspergillosis** - paranasal sinuses or bronchial mucosa colonization followed by allergic reaction
- **Aspergilloma** - **previously formed cavity** (paranasal sinuses, lungs (tumor necrosis, bronchiectasis, evacuated abscess...), adhesion of inhaled conidia, hyphae formation, finally cavity filled with fungal thallus, **no invasion to surrounding tissue**)
- **Chronic pulmonary aspergillosis (CPA)** – chronic pulmonary disease, tissue invasion
- **Invasive aspergillosis** – conidia inhalation and adhesion, growing hyphae invade surrounding tissue, angioinvasion, tissue necrosis and destruction, hematogenous dissemination (CNS, heart, GIT, kidneys, liver)

Aspergillosis – clinical manifestation, diagnosis, treatment

Colonization, bronchial obstruction, allergic bronchopulmonary aspergillosis -
cough, asthma

Antiallergic and symptomatic therapy in most cases

Aspergilloma if bleeding is a threat, surgery and antifungal therapy is indicated

Invasive aspergilosis

Fever refractory to antibiotic treatment, pulmonary infiltrates, hemoptysis, pleuritis.

Complex diagnostic procedure (history, immunology, imaging, microbiology, histopathology)

Microscopy, culture, AFST – site of infection (tissue, BAL)

Galactomannan detection – BAL, CSF, serum – neutropenic

Targeted PCR

Systemic antifungal therapy - **voriconazole, isavuconazole if susceptible**

ARAF – voriconazole + echinocandin, liposomal amphotericin B

Mucormycosis (zygomycosis)

Rhizopus, Mucor, Lichtheimia, Rhizomucor – environment (soil), sporangiospores

Risk factors

- Cellular immunity impairment – severe neutropenia
- Diabetes mellitus, ketoacidosis
- Renal impairment, hemodialysis, iron chelators administration
- Corticosteroid therapy

Pathogenicity factors

Angioinvasivity – adhaerence to endothelial surfaces (receptor-ligand, up-regulated by glucosis and iron abundance)

Immunomodulation

Mucormycosis - pathogenesis

Sporangiospores are inhaled or contaminate bandages or any wound coverage

Rapid growth and tissue destruction, necrosis and haemorrhage due to angioinvasion

Clinical forms

Rhinocerebral – RF diabetic ketoacidosis

Pulmonary – rapidly progressing haemorrhagic-necrotizing pneumonia

Disseminated - angioinvasion, rapid dissemination, **fatal bleeding**

Skin (always suspect dissemination!) or posttraumatic wound infection (burn wounds, hurricane and tsunami associated trauma)

Therapy – **surgery** whenever possible

Amphotericin B lipid complex, isavuconazole

Pneumocystis jirovecii

Ascomycetous fungus previously classified as protozoon

Both sexual and asexual life cycle occurs in **alveolar tissue**

Risk factors

AIDS

Immaturity, premature birth

Cellular immunity impairment


Clinical manifestation

interstitial pneumonia, granulomatous inflammatory process, diffuse alveolar damage

Respiratory distress, low oxygen saturation, dyspnea, long-term course with gradual deterioration of lung functions

Co-trimoxazole both for treatment (high-dose) and prophylaxis (low-dose)





Thank you for your attention